240 related articles for article (PubMed ID: 21681688)
1. Neuroradiological response criteria for high-grade gliomas.
Lutz K; Radbruch A; Wiestler B; Bäumer P; Wick W; Bendszus M
Clin Neuroradiol; 2011 Nov; 21(4):199-205. PubMed ID: 21681688
[TBL] [Abstract][Full Text] [Related]
2. [Neuroradiological response criteria for malignant gliomas].
Bendszus M; Platten M
Nervenarzt; 2010 Aug; 81(8):950-5. PubMed ID: 20669003
[TBL] [Abstract][Full Text] [Related]
3. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
Vogelbaum MA; Jost S; Aghi MK; Heimberger AB; Sampson JH; Wen PY; Macdonald DR; Van den Bent MJ; Chang SM
Neurosurgery; 2012 Jan; 70(1):234-43; discussion 243-4. PubMed ID: 21593697
[TBL] [Abstract][Full Text] [Related]
4. Imaging Criteria in Neuro-oncology.
Nowosielski M; Wen PY
Semin Neurol; 2018 Feb; 38(1):24-31. PubMed ID: 29548049
[TBL] [Abstract][Full Text] [Related]
5. Response assessment in neuro-oncology criteria: implementation challenges in multicenter neuro-oncology trials.
Pope WB; Hessel C
AJNR Am J Neuroradiol; 2011 May; 32(5):794-7. PubMed ID: 21474628
[No Abstract] [Full Text] [Related]
6. Response assessment in neuro-oncology.
Quant EC; Wen PY
Curr Oncol Rep; 2011 Feb; 13(1):50-6. PubMed ID: 21086192
[TBL] [Abstract][Full Text] [Related]
7. Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.
Sharma M; Juthani RG; Vogelbaum MA
Chin Clin Oncol; 2017 Aug; 6(4):37. PubMed ID: 28841799
[TBL] [Abstract][Full Text] [Related]
8. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Wen PY; Macdonald DR; Reardon DA; Cloughesy TF; Sorensen AG; Galanis E; Degroot J; Wick W; Gilbert MR; Lassman AB; Tsien C; Mikkelsen T; Wong ET; Chamberlain MC; Stupp R; Lamborn KR; Vogelbaum MA; van den Bent MJ; Chang SM
J Clin Oncol; 2010 Apr; 28(11):1963-72. PubMed ID: 20231676
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Brain Tumor Response: RANO and Its Offspring.
Eisele SC; Wen PY; Lee EQ
Curr Treat Options Oncol; 2016 Jul; 17(7):35. PubMed ID: 27262709
[TBL] [Abstract][Full Text] [Related]
10. Pros and cons of current brain tumor imaging.
Ellingson BM; Wen PY; van den Bent MJ; Cloughesy TF
Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii2-11. PubMed ID: 25313235
[TBL] [Abstract][Full Text] [Related]
11. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.
Hygino da Cruz LC; Rodriguez I; Domingues RC; Gasparetto EL; Sorensen AG
AJNR Am J Neuroradiol; 2011 Dec; 32(11):1978-85. PubMed ID: 21393407
[TBL] [Abstract][Full Text] [Related]
12. Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints.
Huang RY; Wen PY
Magn Reson Imaging Clin N Am; 2016 Nov; 24(4):705-718. PubMed ID: 27742111
[TBL] [Abstract][Full Text] [Related]
13. Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas.
Youssef G; Wen PY
Curr Neurol Neurosci Rep; 2024 Feb; 24(2):17-25. PubMed ID: 38170429
[TBL] [Abstract][Full Text] [Related]
14. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Wen PY; van den Bent M; Youssef G; Cloughesy TF; Ellingson BM; Weller M; Galanis E; Barboriak DP; de Groot J; Gilbert MR; Huang R; Lassman AB; Mehta M; Molinaro AM; Preusser M; Rahman R; Shankar LK; Stupp R; Villanueva-Meyer JE; Wick W; Macdonald DR; Reardon DA; Vogelbaum MA; Chang SM
J Clin Oncol; 2023 Nov; 41(33):5187-5199. PubMed ID: 37774317
[TBL] [Abstract][Full Text] [Related]
15. Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
Jaspan T; Morgan PS; Warmuth-Metz M; Sanchez Aliaga E; Warren D; Calmon R; Grill J; Hargrave D; Garcia J; Zahlmann G
AJNR Am J Neuroradiol; 2016 Sep; 37(9):1581-7. PubMed ID: 27127006
[TBL] [Abstract][Full Text] [Related]
16. Response Assessment in Neuro-Oncology Clinical Trials.
Wen PY; Chang SM; Van den Bent MJ; Vogelbaum MA; Macdonald DR; Lee EQ
J Clin Oncol; 2017 Jul; 35(21):2439-2449. PubMed ID: 28640707
[TBL] [Abstract][Full Text] [Related]
17. Posttreatment evaluation of central nervous system gliomas.
Shiroishi MS; Booker MT; Agarwal M; Jain N; Naghi I; Lerner A; Law M
Magn Reson Imaging Clin N Am; 2013 May; 21(2):241-68. PubMed ID: 23642552
[TBL] [Abstract][Full Text] [Related]
18. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.
Chinot OL; Macdonald DR; Abrey LE; Zahlmann G; Kerloëguen Y; Cloughesy TF
Curr Neurol Neurosci Rep; 2013 May; 13(5):347. PubMed ID: 23529375
[TBL] [Abstract][Full Text] [Related]
19. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.
van den Bent MJ; Wefel JS; Schiff D; Taphoorn MJ; Jaeckle K; Junck L; Armstrong T; Choucair A; Waldman AD; Gorlia T; Chamberlain M; Baumert BG; Vogelbaum MA; Macdonald DR; Reardon DA; Wen PY; Chang SM; Jacobs AH
Lancet Oncol; 2011 Jun; 12(6):583-93. PubMed ID: 21474379
[TBL] [Abstract][Full Text] [Related]
20. Response assessment challenges in clinical trials of gliomas.
Wen PY; Norden AD; Drappatz J; Quant E
Curr Oncol Rep; 2010 Jan; 12(1):68-75. PubMed ID: 20425610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
